Rifapentine

Tuberculosis Clinical Trials Consortium Study 35

Shortened Regimen for Drug-susceptible TB in Children

Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

Treatment of Latent Tuberculosis in Socially Marginalised Citizens

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment

PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

The Correlate of Risk Targeted Intervention Study

Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

Tuberculosis Prevention for HIV Infected Adults

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine